

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 March 2002 (28.03.2002)

PCT

(10) International Publication Number
WO 02/24918 A1

(51) International Patent Classification⁷: **C12N 15/53**,
9/02, C12Q 1/68

(21) International Application Number: PCT/SE01/02007

(22) International Filing Date:
19 September 2001 (19.09.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0003393-6 22 September 2000 (22.09.2000) SE

(71) Applicant (for all designated States except US): **BIOVIT-
RUM AB** [SE/SE]; S-112 76 Stockholm (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BERKENSTAM, Anders** [SE/SE]; Långholmsgatan 11, S-117 33 Stockholm (SE). **BERTILSSON, Göran** [SE/SE]; Kronobergsgatan 5, S-112 33 Stockholm (SE). **BLOMQUIST, Patrik** [SE/SE]; Korsfararvägen 56, S-181 40 Lidingö (SE).

(74) Agent: **HÖGLUND, Lars**; Biovitrum AB, S-112 76 Stockholm (SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROMOTER SEQUENCES

(57) Abstract: The present invention relates an isolated human Cytochrome P-450 3A7 (CYP3A7) promoter region. The invention also relates to screening methods for agents modulating the expression of CYP3A7, such agents being potentially useful in modulating metabolism of endogenous and/or exogenous compounds, drug interaction, toxicity and/or bioavailability of drugs.



WO 02/24918 A1

PROMOTER SEQUENCES

TECHNICAL FIELD

- 5 The present invention relates an isolated human Cytochrome P-450 3A7 (CYP3A7) promoter region. The invention also relates to screening methods for agents modulating the expression of CYP3A7, such agents being potentially useful in modulating metabolism of endogenous and/or exogenous compounds, drug interaction, toxicity and/or bioavailability of drugs.

10

BACKGROUND ART

- The cytochrome P-450 hemoproteins (P-450) are important metabolizers of both
15 endogenous and exogenous compounds (Nelson et al., 1996). The human P-450 3A superfamily contains three functional members: CYP3A4, CYP3A5 and CYP3A7. The CYP3A4 isoform is the major metabolizer of therapeutic drugs in adults and plays a central role in the steroid hormone metabolism. More than 60% of therapeutic drugs are metabolized by CYP3A4 (Li et al., 1995). While CYP3A4 is the predominant P-450 in
20 adult liver, the CYP3A7 isoform (SEQ ID NOS: 2 and 3) is the major P-450 in fetal liver (Yang et al., 1994). CYP3A7 is also expressed in placenta and endometrium, and in low amounts in adult liver, lung, kidney and tumors (Hakkola et al., 1996; Kivisto et al., 1996; Kolars et al., 1994; Murray et al., 1999; Schuetz et al., 1993). CYP3A7 has been postulated to protect the growing embryo against xenobiotics and steroids that
25 passes the placenta (Schuetz et al., 1993). There are however several procarcinogenes that are converted into their active forms by CYP3A7 or CYP3A4 (Shimada et al., 1996). Consequently, an altered expression of CYP3A7 or CYP3A4 could cause problems by changing steroid homeostasis, by activating substances to make them toxic, or by inactivating drugs.

30

The CYP3A4 and CYP3A7 isoforms are 95% identical on the nucleotide level, indicating a close evolutionary relationship. The substrate specificities for the two isoforms are also similar (Hakkola et al., 1998). Since both CYP3A4 and CYP3A7

expression is controlled by several drugs and hormones, a better understanding of the transcription factor(s) involved in the regulation of the corresponding genes is of great importance in avoiding problems due to drug interaction. The xenobiotics that activate the genes, and their homologues, differ between species (Kocarek et al., 1995). This
5 could be explained by the species difference in the activation profile of the transcription factor that activates CYP3A genes in response to xenobiotics. However, it may be difficult to predict effects on drug metabolism based on experiments done in other species.

10 The nuclear receptor designated Pregnane Activated Receptor, PAR (NR1I2, also called PXR and SXR), has been cloned and found to be activated by several xenobiotics that influence CYP3A4 or CYP3A7 expression (Bertilsson et al., 1998; Blumberg et al., 1998; Kliewer et al., 1998; Lehmann et al., 1998; see also WO 99/19354; WO 99/31129; WO 99/35246; and WO 99/48915). Since PAR response elements (PREs)
15 were found in the proximal CYP3A4 and CYP3A7 promoters and were shown to be responsive to PAR, it has been suggested that PAR is a xenobiotic sensor (Pascucci et al., 1999). It has also been shown that the PAR activation profile resembles the profile of CYP3A gene induction in different species (Barwick et al., 1996; Jones et al., 2000). This has been further supported by transgenic experiments where mice lacking
20 endogenous PAR expressed the human PAR in the liver. The activation of the murine CYP3A11 gene (the CYP3A4 homologue) by xenobiotics was "humanized" in such mice (Xie et al., 2000). The fact that the activation profile of the CYP3A4 and CYP3A7 genes correlates with the species origin of PAR suggests that PAR is the key xenobiotic sensor in CYP3A4 and presumably in CYP3A7 regulation

25 In addition to the PREs identified in the proximal promoter sequences of CYP3A4 and CYP3A7, a xenobiotic response element (XREM) has been identified in the distal part (7.8 to 7.6 kb upstream) of the CYP3A4 promoter (Goodwin et al., 1999). The XREM contained two PREs and were, in collaboration with the proximal PRE, shown to
30 mediate the transcriptional response to rifampicin in the presence of transiently expressed PAR.

Some environmental agents have been shown to disrupt the endocrine functions in many species through a variety of pathways including the change of steroidogenesis. Nonylphenol and phthalic acid, two of these endocrine-disrupting chemicals (EDCs), have been demonstrated to induce PXR-mediated CYP3A expression (Masuyama et al.,
5 2000).

The PAR receptor has a similar DNA binding preference as the Constitutive Androstane Receptor (CAR) (Sueyoshi et al., 1999). CAR and PAR share some xenobiotic and steroid ligands (Moore et al., 2000). CAR has also been shown to activate the CYP2B
10 gene via a phenobarbital responsive element. Recent experiments have shown that although CAR can activate a CYP3A4 XREM reporter, PAR appears to be the dominant transcription factor (Goodwin et al. 1999).

Only the proximal part (1012 bp) of the CYP3A7 promoter sequence has previously
15 been identified (GenBank Accession No. AF181861; SEQ ID NO: 4) and consequently it has not been known whether the distal part of the CYP3A7 promoter contains response elements for transcription factors that could regulate the transcription of CYP3A7.

20

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1

(A) Schematic illustration of the CYP3A7 promoter. Restriction enzyme sites relevant
25 for the cloning of different reporter construct have been indicated. (B) Comparison of the CYP3A7 and CYP3A4 promoters. Regions with high sequence identity (90%) are indicated by an open bar and regions with low identity (~25%). XREM, dNR3 and pNR are shown by black boxes. (C) Sequence comparison of the different PREs from CYP3A7 and CYP3A4. Nucleotides that differ are underlined. The different half-sites
30 of the PREs are indicated by bold letters and by arrows.

Fig. 2

Identification of the XREM as a PAR responsive element in the CYP3A7 promoter.

Schematic drawings of the CYP3A7-luciferase reporter constructs are shown to the left, with the XREM, dNR3 and pNR indicated by black boxes. The graph shows the fold
5 induction of cells treated with 10 μ M rifampicin as compared to vehicle (DMSO). The black columns symbolize cells transfected with a plasmid expressing hPAR-2 and the white columns symbolizes cells transfected with an empty expression plasmid. Data are mean \pm SD for a typical experiment with six values in each group. The experiment has been repeated on five different occasions with similar result.

10

Fig. 3

Identification of CAR as transcription factor for CYP3A7. C3A cells were transfected with Cyp3A7 promoter with (Cyp3A7-9302) or without (CYP3A7-7478) the XREM and with CAR expression vector (CAR) or with empty (pcDNA3) expression vector.

15 Cells were treated with vehicle (DMSO) or 10 μ M of rifampicin or clotrimazol. Relative luciferase values represent luciferase activity compensated for the alkaline phosphatase reporter. The data are mean values \pm SD for six wells of a typical experiment

20 DISCLOSURE OF THE INVENTION

This invention relates to the cloning and sequencing of the upstream promoter sequence (SEQ ID NO: 1) of the CYP3A7 gene. The CYP3A7 promoter sequence shows more than 90% identity to the CYP3A4 promoter up to approximately 8.8 kb upstream.

25 Transient transfection experiments using a reporter plasmid containing the CYP3A7 promoter identified a region containing a XREM-like sequence (positions 3330 to 3551 in SEQ ID NO: 1) as the region containing the PAR response element. We conclude that CYP3A7 is regulated by PAR and that this regulation is mainly mediated via the CYP3A7 XREM. Experiments using a CAR expression vector showed that CAR could
30 upregulate the CYP3A7 reporter and that this regulation was also dependent on the presence of the XREM containing region.

The fact that CAR is not activated in the same sense as PAR suggests that PAR is indeed the major “xenobiotic sensor” in the liver. This is supported by transient transfection experiments where the PAR and CAR expressing plasmids have been titrated (Goodwin et al., 1999). Consequently, substances that activates PAR, and
5 thereby expression of CYP3A4 and CYP3A7, are likely to have an effect drug metabolism and steroid homeostasis.

According to the invention, the identification of (i) PAR as the transcription factor responsible for xenobiotic mediated regulation of CYP3A7, and (ii) upstream response
10 elements for PAR in the CYP3A7 promoter, can be used for the development of screening methods for medically useful agents, e.g. agents modulating metabolism of endogenous and/or exogenous compounds, agents modulating drug interaction, and/or agents modulating toxicity or bioavailability of drugs. Such methods could also be used for screening environmental pollutants for potential endocrine disrupting capacity (cf.
15 Masuyama et al., 2000).

Consequently, in a first aspect this invention provides an isolated human CYP3A7 promoter region comprising the dNR1 nucleotide sequence shown as positions 3425 to 3439 in SEQ ID NO: 1 or the dNR2 nucleotide sequence shown as positions 3469 to
20 3486 in SEQ ID NO: 1. Such a promoter region could more specifically comprise the XREM nucleotide sequence shown as positions 1832 to 3655 in SEQ ID NO: 1. Alternatively, the said isolated human CYP3A7 promoter region can comprise the dNR3 nucleotide sequence shown as positions 3855 to 3869 in SEQ ID NO: 1. The term “promoter region” refers to a region of DNA that functions to control the transcription
25 of one or more genes, and is structurally identified by the presence of a binding site for DNA-dependent RNA polymerase and of other DNA sequences on the same molecule which interact to regulate promoter function.

In another aspect, the invention provides a recombinant construct comprising the human
30 CYP3A7 promoter region as defined above. In the said recombinant construct, the human CYP3A7 promoter region can be operably linked to a gene encoding a detectable product, e.g. a human CYP3A7 gene essentially having a nucleic acid sequence set forth as SEQ ID NO: 2.

The term "linked" indicates that a nucleotide sequence encoding a gene product and an CYP3A7 promoter, or an active fragment thereof, are located within a continuous nucleic acid sequence. The term "operably linked" means that a nucleotide sequence,
5 which can encode a gene product, is linked to the CYP3A7 promoter such that the CYP3A7 promoter regulates expression of the gene product under appropriate conditions. Two nucleotide sequences that are operably linked contain elements essential for transcription, including, for example, a TATA box.

10 The recombinant construct according to the invention could comprise a reporter gene. As used herein, the term "reporter gene" means a gene encoding a gene product that can be identified using simple, inexpensive methods or reagents and that can be operably linked to a CYP3A7 promoter or an active fragment thereof. Reporter genes such as, for example, a luciferase, β -galactosidase, alkaline phosphatase, or green fluorescent
15 protein reporter gene, can be used to determine transcriptional activity in screening assays according to the invention (see, for example, Goeddel (ed.), *Methods Enzymol.*, Vol. 185, San Diego: Academic Press, Inc. (1990); see also Sambrook, *supra*).

In another aspect the invention provides a vector comprising the recombinant construct
20 as defined above. The term "vector" refers to any carrier of exogenous DNA that is useful for transferring the DNA to a host cell for replication and/or appropriate expression of the exogenous DNA by the host cell. A host cell stably transformed with the recombinant construct is an additional aspect of the invention. Such a host cell can be a prokaryotic cell, a unicellular eukaryotic cell, or a cell derived from a multicellular
25 organism. The methods employed to effect introduction of the vector into the host cell are standard methods well known to a person familiar with recombinant DNA methods. The term "transformed" or "transfected" refers to the process by which exogenous DNA is transferred into an appropriate host cell.

30 In a further important aspect, this invention is useful in screening for pharmacological agents that modulate CYP3A7 levels by affecting the transcription of the CYP3A7 gene. As used herein, the term "agent" means a biological or chemical compound such as a simple or complex organic molecule, a peptide, a protein or an oligonucleotide.

For screening purposes, appropriate host cells can be transformed with a vector having a reporter gene under the control of the human CYP3A7 promoter according to this invention. The expression of the reporter gene can be measured in the presence or
5 absence of an agent with known activity (i.e. a standard agent) or putative activity (i.e. a “test agent” or “candidate agent”). A change in the level of expression of the reporter gene in the presence of the test agent is compared with that effected by the standard agent. In this way, active agents are identified and their relative potency in this assay determined.

10

Consequently, this invention includes a method for the identification of an agent capable of modulating CYP3A7 promoter activity, said method comprising the steps
(i) contacting a candidate agent with the human CYP3A7 promoter according to the invention; and
15 (ii) determining whether said candidate agent modulates expression of the CYP3A7 gene.

More specifically, such a method could comprise the steps:

- (i) providing a cell comprising the CYP3A7 promoter region, operably linked to a
20 reporter gene;
(ii) determining a first level of expression of the said reporter gene;
(iii) contacting the said cell with a candidate agent; and
(iv) determining a second level of expression of the reporter gene in the presence of the candidate agent, wherein a difference between the first and second levels of expression
25 indicates that the candidate agent modulates CYP3A7 promoter activity.

It will be understood that agents acting on the human CYP3A7 promoter can be identified by, as an additional step, analyzing direct binding interactions between the candidate agent and the human CYP3A7 promoter. Interactions with large molecules
30 may be studied using techniques such as gel shift analysis, footprinting or NMR (see Latchman, D.S. (Ed.) (1995) Methods for studying transcription factors. In: Eukaryotic transcription factors. Academic Press, London, pp. 17-44). Small molecule compounds which appear to bind reversibly to double stranded DNA without intercalation between

DNA base pairs have been defined. Methods are described by which this non-intercalative binding can be characterized using ultraviolet spectrometry, fluorimetry with ethidium as a probe, viscometry and other hydrodynamic techniques, circular dichroism and nuclear magnetic resonance spectrometry (See Baguley, B.C. (1982) Nonintercalative DNA-binding antitumor compounds. *Mol Cell Biochem* 43: 167-181; Gmeiner, W.H. (1998) NMR spectroscopy as a tool to investigate the structural basis of anticancer drugs. *Curr Med Chem* 5(2):115-135; Wemmer, D.E. & Williams, P.G. (1994) Use of nuclear magnetic resonance in probing ligand-macromolecule interactions. *Methods Enzymol.* 239:739-767)

10

In another important aspect, this invention provides a method for identifying an agent which modulates the association of a CYP3A7 promoter and a transcription factor, comprising the steps:

- (i) contacting a CYP3A7 promoter region according to the invention with said transcription factor;
- (ii) determining a first association between the CYP3A7 promoter region and the transcription factor;
- (iii) contacting the said CYP3A7 promoter region and said transcription factor with a candidate agent; and
- (iv) determining a second association between the CYP3A7 promoter region and the transcription factor in the presence of the candidate agent, wherein a difference between the first and the second association indicates that the candidate agent modulates the association of the CYP3A7 promoter and the transcription factor.

The said method could involve e.g. a solid phase *in vitro* binding assay, or a cell based transcription assay, both of which are well known to the skilled person. When the method involves a cell-based assay, it could comprise the following steps:

- (i) providing a cell comprising the CYP3A7 promoter region, operably linked to a reporter gene, and the said transcription factor;
- (ii) determining a first level of expression of the said reporter gene;
- (iii) contacting the said cell with a candidate agent; and
- (iv) determining a second level of expression of the reporter gene in the presence of the candidate agent, wherein a difference between the first and second levels of expression

indicates that the candidate agent modulates the association of the CYP3A7 promoter and the transcription factor.

In preferable forms of the invention, the said transcription factor could be the Pregnane
5 Activated Receptor (PAR; Bertilsson et al., 1998) or the Constitutive Androstane
Receptor (CAR) (GenBank accession number NM_005122).

MATERIALS AND METHODS

10

Isolation of genomic clones

Two BAC clones, BAC 97c20 and BAC 156P02, were identified by hybridization
screening to contain the CYP3A4 promoter. The screening was done by using a
15 nucleotide fragment (corresponding to positions 9364 to 10434 in GenBank Accession
No. AF185589) specific for the CYP3A4 promoter. The BAC clones were cleaved with
*Bam*HI and the obtained fragments were ligated into pBluescript II KS(+) (Stratagene).
The obtained clones were screened by PCR for the presence of the CYP3A4 promoter
by using primers specific for the published CYP3A4 promoter (GenBank Accession No.
20 AF185589). The sequence for the 5' primer was
5'-TTAATGACCTAAGAAGTCACCAG - 3',
and for the 3' primer:
5'-CGCCTCTCTCTTGCCCTTGTC - 3'.

One clone containing 11.4 kb was sequenced and shown to contain the CYP3A4
25 promoter sequence. Screening with CYP3A7 specific primers,
5'-GACCTAAGAAGATGGAGTGG - 3', and
5'-CATAAAATCTATTA ACTCTCCT - 3',
did not identify any clones containing the CYP3A7 promoter.

30 After identification of the XREM as the PAR responsive region new XREM specific
primers were designed and used to rescreen the original clones. The sequences of the
primers were
5'- TCTAGAGAGATGGTTCATTCCTTTCA - 3' and

5'-TGTTCTTGTGTCAGAAAGTTCAGCTT-3'.

A clone that contained part of the CYP3A7 promoter was isolated and sequenced. This clone contained the CYP3A7 promoter between position -11133 and -3188. In order to isolate the reminding part of the promoter PCR was performed on genomic DNA. The sequences of the primers were

5'-GCTGGGCATGGTGGTATACCTGTAGTA-3' and

5'-agcgatccTGCTGCTGTTTGCTGGGCTGTGT-3'.

The latter primer contains a *Bam*HI site and additional 3 nucleotides not present in genomic DNA (indicated by lowercase letters). This was done in order to clone the

CYP3A7 promoter sequence into a reporter plasmid, see below. The PCR fragment was cloned into pCR2.1/TOPO (Invitrogen) to create the plasmid CYP3A7 -3604/+53-Topo. The fragment obtained by PCR was sequenced. Several independent gene walking experiments confirmed the sequence.

Plasmid constructs

Manipulations of DNA were done using enzymes and the Rapid DNA Ligation Kit supplied by Roche. The plasmids were transformed into TOP10 cells (Invitrogen) and grown in LB. Plasmids was isolated using the Plasmid Maxi kit (Qiagen). The CYP3A4

promoter was amplified by PCR, using the primers

5'-CAGCACTGAACTCTAGCCTGGGCAACA-3', and

5'-agcgatccTGCTGCTGTTTGCTGGGCTGTGT-3',

in order to introduce a *Bam*HI site immediately downstream of position +53. (Lower case letters denotes bases not present in the CYP3A7 sequence.)

A *Bam*HI/*Kpn*I fragment from the PCR product was ligated into the *Bgl*III and *Kpn*I sites of the pGL3-Basic Vector (Promega) in order to create the vector CYP3A4-3192. A *Bam*HI/*Eco*RV encompassing -10466 and -3096 of the CYP3A4 promoter sequence was cloned into the pCR2.1/TOPO vector (Invitrogen). A *Kpn*I fragment from the obtained vector were cloned into the *Kpn*I site of the CYP3A4-3192 vector. The final vector, CYP3A4 -10466, contained CYP3A4 promoter sequence from -10466 and +53 cloned into the *Kpn*I and the *Bgl*III sites, the latter was inactivated upon cloning, of the

pGL3-Basic Vector. The vector also contained a *SacI* site just upstream of the promoter sequence, this site originated from the pCR2.1/TOPO vector.

A *Bam*HI/*Hind*III fragment from CYP3A7 -3604/+53-Topo was cloned into
5 pBleuscript II KS(+) in order to create the plasmid pBS-CYP3A7 -3604. The
*Xho*I/*Hind*III fragment encompassing -7803 and -3604 of the CYP3A7 promoter was
cloned into pBS-CYP3A7 -3604 to create pBS CYP3A7 -7803. A *Bam*HI/*Sma*I
fragment from this plasmid was cloned into pGL3-Basic in order to create the plasmid
3A7 -6444. The 3A7 -9302 plasmid was created by ligating a *Nhe*I/*Sma*I fragment
10 (position -9302/-6444) from the CYP3A7 promoter into the 3A7 -6444 plasmid. The
3A7 -7478 plasmid was created by cutting the CYP3A7 -9302 with *Spe*I and *Nhe*I and
religating. The 3A7 -6444 (-9302/-7479 ins) plasmid was created by ligating the
-9302/-7479 *Nhe*I/*Spe*I fragment of the Cyp3A7 promoter into the *Nhe*I site of 3A7
-6444.

15
Expression vector for full-length nuclear receptor PAR-2 and the pRSV-AF reporter
plasmid have been described previously (Bertilsson et al., 1998). The CAR expression
vector was prepared by amplifying full-length CAR by RT-PCR from total RNA
prepared from C3A/HepG2 cells using the primers
20 5'-CGGAATTCTCAGCTGCAGATCTCCTGGA-3', and
5'-CGGGATCCATGGCCAGTAGGGAAGATGA-3'.
hCAR was cloned into pcDNA-3 vector (Invitrogen) using restriction enzymes *Bam*HI
and *Eco*RI.

25
Cell based reporter assays

Six well plates were seeded with 0.5×10^6 C3A cells. The cells were maintained in
MEM with phenol red containing L-glutamine and supplemented with nonessential
30 amino acids. The medium also contained 10 % foetal bovine serum (life Technologies).
The cells were allowed to settle for 24 hours before the medium was replaced by
medium containing 10% charcoal treated foetal bovine serum (Hyclone Laboratories).
Each well was transfected with 0.1 µg RSV-AF, 2 µg of the indicated reporter and 0.5

µg of the expression vector for PAR-2, CAR or the empty expression vector, pcDNA3. FuGENE 6™ Transfection Reagent (Roche) was used according to recommendations from the manufacturer. After 24 hours the medium was replaced by fresh medium containing 10% charcoal treated foetal bovine serum. The cells were induced by the
5 addition of either DMSO (vehicle) or the indicated compound at a concentration of 10 µM. After induction for 48 hours the medium was analysed for the alkaline phosphatase activity and the luciferase activity was measured in the cell lysate as described (Bertilsson et al., 1998). DMSO, rifampicin and clotrimazole were purchased from Sigma-Aldrich.

10

Throughout this description the terms “standard protocols” and “standard procedures”, when used in the context of molecular biology techniques, are to be understood as protocols and procedures found in an ordinary laboratory manual such as: Current Protocols in Molecular Biology, editors F. Ausubel et al., John Wiley and Sons, Inc.
15 1994, or Sambrook, J., Fritsch, E.F. and Maniatis, T., Molecular Cloning: A laboratory manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1989.

EXAMPLES

20

EXAMPLE 1: Cloning of the CYP3A4 and CYP3A7 promoter sequences

More than 10 kb of upstream promoter sequence for CYP3A4 and CYP3A7, respectively, was cloned and sequenced. Alignment of the two sequences indicates an
25 extremely high sequence identity up to -8.8 kb (Fig. 1b). The sequence identity is 90 %, which is the same degree of conservation as within the coding sequence. Above -8.8 kb the sequence identity is only random (25%). The published CYP3A4 promoter sequence (GenBank Accession No. AF185589) is identical sequence with the obtained CYP3A4 sequence, with exception for a few base pair changes, which could be due to
30 polymorphism. None of these changes was located in any regions known to be important for the regulation of the CYP3A4 promoter. In similarity with Goodwin et al., we noted 5 bp mismatches compared to the previously published sequence for the CYP3A4 proximal promoter (Goodwin et al., 1999; Hashimoto et al., 1993).

The sequence of the obtained CYP3A7 promoter is shown as SEQ ID NO: 1.

Transcription start is at position 11,134 in SEQ ID NO: 1. Positions 10,120 to 11,129 in SEQ ID NO: 1 correspond to positions 3 to 1012 in the previously published proximal

5 CYP3A7 promoter (SEQ ID NO: 4).

EXAMPLE 2: Identification of the PAR responsive element in the CYP3A7 promoter

10 Transient transfection experiments using different deletion mutants of the CYP3A7 promoter identified the region between -9302 and -7479 (positions 1832 to 3655 in SEQ ID NO: 1) to contain the major PAR responsive element (Fig. 2). This region encompasses the XREM previously identified (Goodwin et al., 1999). The induction of the CYP3A7 reporter was dependent on exogenously added PAR (compare the white
15 and the black bars in Fig. 2).

We conclude, based on sequence homology, that the CYP3A7 promoter contains a XREM sequence located between -7804 and -7583 (positions 3330 to 3551 in SEQ ID NO: 1). A closer examination of the distal nuclear receptor binding motifs (dNRs)
20 previously identified in CYP3A4 (Goodwin et al., 1999) showed that dNR1 (positions 3425 to 3439 in SEQ ID NO: 1) was identical to the corresponding motif in CYP3A4 (Fig. 1c). The motifs dNR2 (positions 3469 to 3486 in SEQ ID NO: 1) and dNR3 (positions 3855 to 3869 in SEQ ID NO: 1) each contained a single base pair change in comparison with CYP3A4. There are two base pair changes in the CYP3A7 proximal
25 PAR response element (pNR) compared with pNR in CYP3A4 (Pascucci et al., 1999).

EXAMPLE 3: CAR can upregulate the CYP3A7 promoter via the XREM

30 PAR shares DNA binding specificity and has overlapping ligand specificity with the nuclear receptor CAR (Moore et al., 2000). In order to investigate whether CAR could influence the activity of the CYP3A7 promoter we transfected cells with CYP3A7 reporters that either contained (CYP3A7-9302) or lacked (CYP3A7-7478) the region

containing the XREM. The results (Fig. 3) indicate that CAR is a strong activator of CYP3A7 and that this is dependent on the presence of the XREM containing region. The CAR dependent induction of CYP3A7 reporter could be reduced by using a CAR inhibitor, clotrimazole.

5

REFERENCES

- Barwick, J. L., Quattrochi, L. C., Mills, A. S., Potenza, C., Tukey, R. H., and Guzelian, P. S. (1996). Trans-species gene transfer for analysis of glucocorticoid-inducible transcriptional activation of transiently expressed human CYP3A4 and rabbit CYP3A6 in primary cultures of adult rat and rabbit hepatocytes. *Molecular Pharmacology* 50, 10-6.
- 10 Bertilsson, G., Heidrich, J., Svensson, K., Asman, M., Jendeberg, L., Sydow-Backman, M., Ohlsson, R., Postlind, H., Blomquist, P., and Berkenstam, A. (1998). Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. *Proceedings of the National Academy of Sciences of the United States of America* 95, 12208-13.
- 15 Blumberg, B., Sabbagh, W., Jr., Juguilon, H., Bolado, J., Jr., van Meter, C. M., Ong, E. S., and Evans, R. M. (1998). SXR, a novel steroid and xenobiotic-sensing nuclear receptor. *Genes & Development* 12, 3195-205.
- 20 Goodwin, B., Hodgson, E., and Liddle, C. (1999). The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. *Molecular Pharmacology* 56, 1329-39.
- 25 Hakkola, J., Raunio, H., Purkunen, R., Pelkonen, O., Saarikoski, S., Cresteil, T., and Pasanen, M. (1996). Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy. *Biochemical Pharmacology* 52, 379-83.
- 30

- Hakkola, J., Pelkonen, O., Pasanen, M., and Raunio, H. (1998). Xenobiotic-metabolizing cytochrome P450 enzymes in the human feto-placental unit: role in intrauterine toxicity. *Critical Reviews in Toxicology* 28, 35-72.
- 5 Hashimoto, H., Toide, K., Kitamura, R., Fujita, M., Tagawa, S., Itoh, S., and Kamataki, T. (1993). Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. *European Journal of Biochemistry* 218, 585-95.
- 10 Jones, S. A., Moore, L. B., Shenk, J. L., Wisely, G. B., Hamilton, G. A., McKee, D. D., Tomkinson, N. C. O., LeCluyse, E. L., Lambert, M. H., Willson, T. M., Kliever, S. A., and Moore, J. T. (2000). The pregnane x receptor: A promiscuous xenobiotic receptor that has diverged during evolution. *Molecular Endocrinology* 14, 27-39.
- 15 Kivisto, K. T., Griese, E. U., Fritz, P., Linder, A., Hakkola, J., Raunio, H., Beaune, P., and Kroemer, H. K. (1996). Expression of cytochrome P 450 3A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours. *Naunyn-Schmiedebergs Archives of Pharmacology* 353, 207-12.
- 20 Kliever, S. A., Moore, J. T., Wade, L., Staudinger, J. L., Watson, M. A., Jones, S. A., McKee, D. D., Oliver, B. B., Willson, T. M., Zetterstrom, R. H., Perlmann, T., and Lehmann, J. M. (1998). An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. *Cell* 92, 73-82.
- 25 Kocarek, T. A., Schuetz, E. G., Strom, S. C., Fisher, R. A., and Guzelian, P. S. (1995). Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. *Drug Metabolism & Disposition* 23, 415-21.
- 30 Kolars, J. C., Lown, K. S., Schmiedlin-Ren, P., Ghosh, M., Fang, C., Wrighton, S. A., Merion, R. M., and Watkins, P. B. (1994). CYP3A gene expression in human gut epithelium. *Pharmacogenetics* 4, 247-59.

- Lehmann, J. M., McKee, D. D., Watson, M. A., Willson, T. M., Moore, J. T., and Klierer, S. A. (1998). The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. *Journal of Clinical Investigation* 102, 1016-23.
- 5 Masuyama, H., Hiramatsu, Y., Kunitomi, M., Kudo, T., and MacDonald, P. N. (2000). Endocrine disrupting chemicals, phthalic acid and nonylphenol, activate Pregnane X receptor-mediated transcription. *Molecular Endocrinology* 14, 421-428.
- 10 Moore, L. B., Parks, D. J., Jones, S. A., Bledsoe, R. K., Consler, T. G., Stimmel, J. B., Goodwin, B., Liddle, C., Blanchard, S. G., Willson, T. M., Collins, J. L., and Klierer, S. A. (2000). Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. *Journal of Biological Chemistry* 275, 15122-7.
- 15 Murray, G. I., McFadyen, M. C., Mitchell, R. T., Cheung, Y. L., Kerr, A. C., and Melvin, W. T. (1999). Cytochrome P450 CYP3A in human renal cell cancer. *British Journal of Cancer* 79, 1836-42.
- 20 Nelson, D.R. et al. (1996). P450 superfamily. Update on new sequences, gene mapping, accession numbers and nomenclature. *Pharmacogenetics* 6, 1-42
- Pascussi, J. M., Jounaidi, Y., Drocourt, L., Domergue, J., Balabaud, C., Maurel, P., and Vilarem, M. J. (1999). Evidence for the presence of a functional pregnane X receptor
25 response element in the CYP3A7 promoter gene. *Biochemical & Biophysical Research Communications* 260, 377-81.
- Shimada, T., Yamazaki, H., Mimura, M., Wakamiya, N., Ueng, Y. F., Guengerich, F. P., and Inui, Y. (1996). Characterization of microsomal cytochrome P450 enzymes
30 involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. *Drug Metabolism & Disposition* 24, 515-22.

- Schuetz, J. D., Kauma, S., and Guzelian, P. S. (1993). Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta. *Journal of Clinical Investigation* 92, 1018-24.
- 5 Sueyoshi, T., Kawamoto, T., Zelko, I., Honkakoski, P., and Negishi, M. (1999). The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. *Journal of Biological Chemistry* 274, 6043-6.
- 10 Tateishi, T., Nakura, H., Asoh, M., Watanabe, M., Tanaka, M., Kumai, T., Takashima, S., Imaoka, S., Funae, Y., Yabusaki, Y., Kamataki, T., and Kobayashi, S. (1997). A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. *Life Sciences* 61, 2567-74.
- 15 Xie, W., Barwick, J. L., Downes, M., Blumberg, B., Simon, C. M., Nelson, M. C., Neuschwander-Tetri, B. A., Brunk, E. M., Guzelian, P. S., and Evans, R. M. (2000). Humanized xenobiotic response in mice expressing nuclear receptor SXR. *Nature* 406, 435-439.
- 20 Yang, H. Y., Lee, Q. P., Rettie, A. E., and Juchau, M. R. (1994). Functional cytochrome P4503A isoforms in human embryonic tissues: expression during organogenesis. *Molecular Pharmacology* 46, 922-8.

CLAIMS

1. An isolated human CYP3A7 promoter region comprising the dNR1 nucleotide sequence shown as positions 3425 to 3439 in SEQ ID NO: 1.
2. An isolated human CYP3A7 promoter region comprising the dNR2 nucleotide sequence shown as positions 3469 to 3486 in SEQ ID NO: 1.
3. The isolated human CYP3A7 promoter region according to claim 1 or 2 comprising the XREM nucleotide sequence shown as positions 1832 to 3655 in SEQ ID NO: 1.
4. An isolated human CYP3A7 promoter region comprising the dNR3 nucleotide sequence shown as positions 3855 to 3869 in SEQ ID NO: 1.
5. The isolated human CYP3A7 promoter region according to any one of claims 1 to 4, comprising the nucleotide sequence set forth as SEQ ID NO: 1.
6. A recombinant construct comprising the human CYP3A7 promoter region according to any one of claims 1 to 5.
7. The recombinant construct according to claim 6 wherein the human CYP3A7 promoter region is operably linked to a gene encoding a detectable product.
8. The recombinant construct according to claim 7 wherein said gene encoding a detectable product is a human CYP3A7 gene essentially having a nucleic acid sequence set forth as SEQ ID NO: 2.
9. A vector comprising the recombinant construct according to any one of claims 6 to 8.
10. A host cell stably transformed with the vector according to claim 9.

11. A method for identification of an agent capable of modulating CYP3A7 promoter activity, said method comprising the steps
- 5 (i) contacting a candidate agent with the human CYP3A7 promoter according to any one of claims 1 to 5; and
- (ii) determining whether said candidate agent modulates expression of the CYP3A7 gene.
12. The method according to claim 11 comprising the steps:
- 10 (i) providing a cell comprising the CYP3A7 promoter region, operably linked to a reporter gene;
- (ii) determining a first level of expression of the said reporter gene;
- (iii) contacting the said cell with a candidate agent; and
- (iv) determining a second level of expression of the reporter gene in the presence
- 15 of the candidate agent, wherein a difference between the first and second levels of expression indicates that the candidate agent modulates CYP3A7 promoter activity.
13. A method for identifying an agent which modulates the association of a CYP3A7 promoter and a transcription factor, comprising the steps:
- 20 (i) contacting a CYP3A7 promoter region according to any one of claims 1 to 5 with said transcription factor;
- (ii) determining a first association between the CYP3A7 promoter region and the transcription factor;
- 25 (iii) contacting the said CYP3A7 promoter region and said transcription factor with a candidate agent; and
- (iv) determining a second association between the CYP3A7 promoter region and the transcription factor in the presence of the candidate agent, wherein a difference between the first and the second association indicates that the candidate
- 30 agent modulates the association of the CYP3A7 promoter and the transcription factor.

14. The method according to claim 13, wherein the method is a solid phase *in vitro* binding assay.
15. The method according to claim 13, wherein the method is a cell based
5 transcription assay.
16. The method according to claim 15 comprising the steps:
(i) providing a cell comprising the CYP3A7 promoter region, operably linked to a reporter gene, and the said transcription factor;
10 (ii) determining a first level of expression of the said reporter gene;
(iii) contacting the said cell with a candidate agent; and
(iv) determining a second level of expression of the reporter gene in the presence of the candidate agent, wherein a difference between the first and second levels of expression indicates that the candidate agent modulates the association of the
15 CYP3A7 promoter and the transcription factor.
17. The method according to any one of claims 13 to 16, wherein the transcription factor is the Pregnane Activated Receptor (PAR).
- 20 18. The method according to any one of claims 13 to 16, wherein the transcription factor is the Constitutive Androstane Receptor (CAR).


Fig. 1

Fig. 2





Fig. 3



- 1 -

SEQUENCE LISTING

<110> Biovitrum AB

<120> Promoter sequences

<130> 00352

<160> 4

<170> PatentIn version 3.0

<210> 1

<211> 11186

<212> DNA

<213> Homo sapiens

<400> 1

```

ggatccagtt tcagctttct acatatggct agccagtttt cccagcacca tttattaaat      60
agggaatcct ttccccattg cttgtttttg tcaggtttgt caaagatcag atggttgtag      120
atgtgtggtg tttgttctga ggctctgtt ctgttccatt ggtccatata cctgttttgg      180
tactagtacc atgctctttt ggttactgta gccttgtagt atagtttgaa gtcaggtagc      240
gtgattcctc cagctttgct ctttttgctt aggattgtct tgggaatgtg ggctcttttt      300
tggttccata tgaaatttaa agtagttttt tttccaattc tatgaagaaa gtcattggta      360
acttgatggg gatggcattg aatctataaa ttaccttggg aagtatggcc attttcacga      420
tattgattct tcctatccat gagcatggaa cattcttcca tttgtttgtg tcctctttga      480
ttttgttgag cagtggtttg tagttctcct tgaagaagtc cttcacctcc ctttaatttg      540
gattactaga tttttatttc tcttagtaac aattgcaaat gggagttcac tcatgatttg      600
gctctctttc tgttattggg gtataggaat gcttgtgatt tttgcgcatt aattttgtat      660
cctgagactt tgctgaagtt gcttatcagc ttaaaaggat tttgggctga gacgatgggg      720
ttttctaaat atacaatcat ggcacttgca aacaggaaca atttgacttc ctcttttcct      780
aattgaatac cctttatttc tttttcttgc ctgattgccc tggccagaac ttccaatact      840
atgttgaata agagtcatga gtgagggcat cgttgtcttg tgctgggttc aaagtttttg      900
cccattcagt atgatttttg ctgtggtttt gccataaata gctcttatta ttttgagata      960
cgttccacca atacctactt tattgagagt ttttagcagg aagggtgtt gaattttgtc     1020
gaaggccttt tctacatcta ttgagacaat tatgtggttt ttaaatcggt gattctgttt     1080

```

atgtgatgga ttacatttat taatttgcat atgttgaacc agccttgcat cccagggatg	1140
aagcccactt gattgtagtg gataagcttt ttgatgtgct gctggattca gtttgccagt	1200
attttattga ggattttggc atcaatgttc atcagggata ttggtctaaa attctctttt	1260
tttgttgtgt ctctgccagg ctttggtatc aggatgatgc aggcctcaga aactgagtta	1320
gggaggattc cctcattttc tattgattgg aatagtttca gaaagaatgg taccagctac	1380
tctttgtacc tctggtagaa ttcagctgtg aatccatctg gtcctggact ttttgggttg	1440
taggctatta attattgcct caatttttagg gcctgttatt ggtctattca gacattcaac	1500
ttcttcccgg tttggctctg ggagggttta tgtgtccagg aatttatcca tttcttctag	1560
attttctagt ttatttgtgt agagggtgtt atagtattgt ctgatggtag tttgtatttc	1620
tgtgagatcg gtggtgatat cccctttatc attttttatt gcatctattt aattcttctc	1680
tcttttcttc tttattattc tggctggcgg tctgtcaatt tttttgatct tttcaaaaaa	1740
ccagctcctg ggtttcactg attatttgaa gggttttttg tgtctctatt tctttcagtt	1800
ctcctgtgat cttagttatt tcttgccttc tgctagcttt tgaatgtgtt tgctcttcct	1860
tctctagttc tttgaattgt gatgttacag tgttgatttt agatctttcc tgctttctct	1920
tgtggtcatt tagtgctata aatttccctc tacacattgg tttacatgtg tctcagagat	1980
tctggtatgt tgtgtctttg ttctcattca tttcaagaac atctttactt ctgccttcat	2040
tttgttattt gccagtagt cattcaggag caggttgttc agtcttcatg tagttgtgtg	2100
gttttgagtg agtttcttaa tcctgagttc taatttgatt gcactgttgt ctgagagaca	2160
gtttgttgtg atttccattc ttttacattt actgagcatg ctttatgtcc cattatgtgg	2220
tcaatttttag aataagtgtg atgtgatgct gagaagaatg tatattctgt tgatttgggg	2280
tgtggagttc tgtagatgtc tattcagtc cactgggtgca gagctgagtg gacatgaaca	2340
ttttatcaaa gaagaaacac agctatcaaa aatccagaaa tattgaacct tgtaataaat	2400
aaagtggctg gcctctgggt cattcctgta atctcagtc tttgaaaggc tgagaaagga	2460
ggatcacttg aggccacaag ttcaagacca tcctagacaa gtcagttcaa gaccagactt	2520
catgtctaca aaacatcaaa aaattagcca ggcattggta tgcattgcctg tcatcccagc	2580
tactcaggag gctgaggcag gaggattgct tgagcctggg agattgaagt ggcagtgagc	2640
catgattgtg ccattgcact ccagcctggg caatgcatca agactctgtc taaacaataa	2700
taataataat agtaatagta ataataataa taataaagaa aacgggttggg acgccattcc	2760
ttacttattc aatacacaaa gttaaaagca atttctactt tctctatttt tttattacta	2820

aaaaaagctg aaccattctc acagcctgaa atgcttctca ccttcccctc ttctatacaa	2880
acatttctct gttgatgata atgcagacag tctctccttt aggaatactt cacaccaggt	2940
agttccagat ccccttatct ctgccttccc agagctcctg gtgtctcccc agttccctct	3000
gtgtggtgaa gtacccccac cttgggtctc agcatgactc gttctttgaa ggtcttggtc	3060
acattttccc ttatggttct gttcccctgt gttgtgtcac agcactgggc agagtggaca	3120
accattcac accgatagag agggcccat ggttctggag ataaccatgt aactgatcag	3180
aatagggcat tgagggctgg gtgtcaggca tgggctgcac ttgggtgggc agggcccctg	3240
gaaagtcaca ggatttgga agcttcttag taacatctct ccttggggtc ctcttggaac	3300
ttcatgcccg atgctggatg ctggtttatt ctcgagagat ggttcattcc aataatcaat	3360
gaaactcatg tcccaactaa agttcataaa ctccagtttg taaactgaga taatctcagc	3420
tgaatgaact tgctgacct ctgctttccc ccagcctctc agtgcccttg aaatcatgtc	3480
agttcaagca gcccctagag gcattacaat gtttagttat ttcagtgttt attaaacctt	3540
gccctatgct gaccocaggt gaatcacaag ctggacttct gacaaggaca agctatgata	3600
ttcttttcaa ttacagaaaa agtaagttaa ctgataggat tttttaaaga tgttactagt	3660
tttggaagg taatttgtgc acatggtaaa caagaaggta taagaggata atgcttttat	3720
actgctgaga ataatgtttt ctctaatttt ttttggtaga tgctttcatc agattaataa	3780
aattcactgc tgttagttgt tgaaggtttt ttatatcatg aatgggagtt gaatattatc	3840
atgtattatt aatatattat tattgaacta gcaaaggctc ttctaaaac aattgagatg	3900
atcttataat cgttctcctt taatctgttg atgagatcat tggatattat actttttctc	3960
tgttaaactat tcttgagtct caggttttaa ttcaacttgg tcatggtgta tcatcttga	4020
acactcctgt ctctggcttg ctactattgt gttcagcatt tttgcactga tgccgatgaa	4080
tgagactggc atgtcatctt cctttgcggc cctgattttt ttcagatttg gatcatgtgg	4140
ccctcattga atgagttggg tgtgatgcct tctttttcat gtatctggat tgatgggaca	4200
ctttggagtc tctccagatg gccctcaatg gtccctgcct cctcattgtt aggcctcctag	4260
gcaacccttt ctcatctctg gtaggcccag gaacctgtgg gttttatgtt tgtttggttg	4320
tttggttggt tgttttttga gttggagtcc tgctttgtct ccaggtctgg ggttggagtg	4380
caatggcctg atctcgccc actgcaacct ccacctcctg gggtcaagtg attctcctgc	4440
ctcagccttc tgtgtagctg ggattacagg catccaccac cactcctggc taatttttgt	4500
attttttagta gagacggggg tttacaatat aggccattgt gatctcttgg acaggctagt	4560

- 4 -

ctcaaattcc	tgacctcatg	atctgcctgc	ctcagcctcc	caaagtgcctg	agattacagt	4620
tttgtgcctc	cacacacagt	gaatctgtgg	tttttaaaag	ctcctcatgc	atgtgaattc	4680
tgtgagcatc	ccgggatgac	agccactgtg	tgtccagctg	ttaaaactgt	gagaaagcac	4740
cagcgggacc	ctctccagca	tttgcttgct	gtggtcatga	aagaggcttg	ttggggagat	4800
gatgccttgg	ttgactcctg	aaggatgggt	aggaatgcac	cagatggaag	ctggggttga	4860
cccagtctat	gctaaagaac	agcttgtgtg	gacacaagga	gacacgaaca	catcattttt	4920
gcagagcctg	gggagtagcc	aatcgcacca	tttgcttaaa	acaccgtgta	cagttggaga	4980
agtggactga	gacaggctga	agaagctaac	agtggccaga	tgagaaaggg	tcttgtgtta	5040
cttcctagat	atacttagat	tttatcctgt	gagtgatagg	aacagttgca	gggactgaag	5100
ccaaggaagc	atgctttaag	attccatggt	ttttgagatg	ctgtctgggtg	gctgagtagg	5160
gaattccctg	gataagtact	gcccagggtg	ggcaaaagaa	gctaggaggt	tactgaaata	5220
aggagtatga	gaaatgggtg	aggttttgct	gatgttttgt	aacacatctc	atgacaatct	5280
tcatttcctt	caccaatttc	ctgtttcatt	aattcccttc	cacgtgctct	tctgaaattt	5340
gcctcatatt	ctttgatttc	tcttttacat	gttggtttca	tcacctttta	ctttttgctt	5400
tcttgaaac	acaaatgatt	ctgattgtga	catgtcagaa	ttatttgcaa	cattccccct	5460
tctgctgaaa	catgagctca	ctgaatacac	aatttagtaa	agtgtaggat	gcacatgttg	5520
ttttcatggg	cataaccagc	tctgtagcat	tttataacta	cactggcagt	gtgctgggag	5580
gtgtagagag	aaatatttat	ctcatgtgtg	gctgacacaa	cctgccaaagt	tgtttttagga	5640
gccttcttgg	aatcccagca	agaacaccac	tgatgcaatt	tgaaatcaca	atgtcctgct	5700
ccatgccttg	gcttcatggc	ttagtcacgt	ctgaagtcta	tttctaacta	tctgtttcca	5760
catctataaa	gtatgagtta	aatcatccta	atactactca	tcttacaaag	ttttcttgct	5820
gatattagga	gagttgggaa	agaactgtat	aaattatgaa	gtgccatgga	gatgttggtg	5880
gttactttat	caagaaatag	acactccaga	atagagtaga	aagaaaacag	ttatgattaa	5940
gtcctcctcc	tcttcttttt	ttttaattta	caaagaaagg	tttaattgag	tcacagttcc	6000
atatggttgg	ggaggctcag	aaaacttgca	atcatggcag	ttggcaaagt	ggaagaaggc	6060
accttcttca	caaggtggca	ggagagagag	agctcctctt	cttttttggt	gtaaagtcta	6120
cagaagtgca	tatacttcag	ggcaagggca	ggcaggggaga	agaaaggaca	ttgcttcacc	6180
ccagtcctca	ctgacaagtt	tgctttggga	cttcattttg	tcccagcata	tgggacagag	6240
ctctggccac	taccatttca	gaaggcctga	gctgcattgc	tagttcccca	ctaactctgt	6300

gtgtccttgg gcaaggctgg gcttatgtca aaagattatg accctgggct ctccagctac	6360
agaatctaca tatgaatcct ggctctgcta gagcaattag tgacgtaacc ttggatgggt	6420
cagttaacct tcctgtggct tagtttgctc atctgtaaaa tagggatcat aacaacatca	6480
ataccatggg ttgttagaca gattgaatca gttaatgcag ggtaaatact tagcatgaca	6540
cgtattcact atcatttcct tgagtaaaag ctgagtgtga gtgggtgtga gaatgtgtga	6600
aaccttttca ctgcaatctc agttaagaaa cccatccata atttaaagtt cagggcctaa	6660
atgggtgggt atcttctccc agttgcatcc tatcccacct ttgctcttct cctgcccgt	6720
ggagctgttg gtctttgatt gggctggaag acctggtgga ccctaagtga tctataagag	6780
aatgagaata gaggacaggg aatgtcttca aaactcctag agggacacag aggctgagag	6840
gcaggcagtc ctgcaggggt cttctgattg ggacaaggag gaccttggtc ttcataaggcc	6900
aattctggtc aatttcccc atggacagat gaggaaacag atccaggaat atccaaggtc	6960
tcacacttcc catctgtcaa gtcttggtga ttctgttgta ttcattgtctt tcaaagagag	7020
agagagttta aggaaagaaa gaaggatcaa ctgtgtctga tatcactggg agcttaagta	7080
aagggttctt ttacttcata gcatttttcc caatttgtaa ttcagtatta tttttgtcac	7140
tgtttagtat ctctttgtcc tattagagag atagcttcat caggacaagg attttgattc	7200
tttaatatatt agtgcttgcc acatgccttg aacacagcag gcatacagac taaccaacat	7260
acagtggcat cgaagtgaga cacctacctc ctccagtgcc tagagtacat gtccatggac	7320
ctgtcactct cctcaacacc acccctaagc atgaggcccg aaagcattgc taatcccctc	7380
ctccagccac caaaacttaa aggccaggtg tgggtggctcc tatctgaaat ctcagaactt	7440
taggagacag cagcaggagg atcacttgag gccaggaatt tgagacgagc ctgggcaaca	7500
tagctagaca ccatctgtac taaaaattag ctgggcatgg tggataacct gtagtaccag	7560
ctactaagga ggctgaggta ggaggatcac ttgaaccag gaggtggaag ctacagtga	7620
ctataaccac agcactgaac tccagcctga gcaacagagt gagaccctgc ctcaaaacaa	7680
tttcaaaaat aaataaataa aaacaaaact tagataccac gtgggtcacc caacatgcaa	7740
aatcaagttt tcccctactg agaagaatgg ggacttgaga gctgagttac agagagataa	7800
tctgcctttt tttttttttt tttggtttac atcctcaaga tcatgacctg tgaaatttga	7860
atctaataca caaatcattc cagagcaatg ttgcttctgc ctaccacgag taattcactt	7920
ggccactgga agtcagaaca agcttcccag aagagaggta ccacttggac taccaatata	7980
aaaggatgaa aatatcggag tgaagggtgt ccttgcatca ctgagtcctt ggacagcctg	8040

tccactcatg ctgatatctg agcctaatagc ttctctgaat gttgagattt aactttgatc	8100
caatgaaacc agaccaagaa agaagaaacg tctttcattg ttgataagga catgattttt	8160
ctcacaattt tatgattatt ttcccttagc tgtcctataa ttatctgctt atttgtctct	8220
tctccatgtg cttagggtag aaagttgacc aagaccaaga ataatgtctg ggagcacaat	8280
actgacagca cagctttaaa aacatgatga atgctttaat acaggaaatg agtaggggag	8340
aggcaagtgg tgcttgggtg ttcttccaat gcatagtatc ttccttgaca cagtcagtgc	8400
agctctcagt aggcaagtcc ctacatgtta gaagatgtta ctttctgtgg aattaggtgg	8460
cagaacatgc cttcaattat ttccctttgc agaacaacac caatttcatt agttaggaca	8520
gagtgtctggc tgcatttgaa ttccaagcaa cgattagtct atcactgttg gtatagattc	8580
caaccagtca caccacctcc tgaagtttgt tgggcaggta aatcttcac ttagaataaa	8640
aatcatctta gccaaagtaag tgtttttagag gaaagaagaa aacataatcg tttccataag	8700
agttttgttt ctaaaaaaat aagaaaggct ctttgttttag gtgagctaata gaagttgttg	8760
atagttatca gatgacactg gaatctttac ttgccagaat gtgttctgtg cacctctcgg	8820
tgtggcaaca tagagagggg gatcctccag caatgccatt gatatgggtca gaaactgcat	8880
ctttctttct cctgtctgag atgggggtcct ttgttctaga aaaccagggt ggtgccactg	8940
ggagtaaccc ttgagacagg aacacgaatc tcaaccaatt tctggttgca gccttgagtc	9000
ttactatttg ccatagtgat gcttagcaag gaatggcagg tgcaccagag cagcagagga	9060
cctaatatct cccttcctgt taacttttta taatatatta ttgtgatcag tatcagttgg	9120
gaagctactt gcagtcactg agcctcagtt tctacatctg taaactgggg atagtagcat	9180
ggccctatth aatgtgtctc gcgaagccac tgaaaggaga cagaaatgta ccagaattcc	9240
ctggactttt atcctacttc tcttggggat tgtcaccac ctaccctgtg ctgtcctttg	9300
ttgctttgac gctgtcactt cttttcttag gtacctctct gtaggggtcc attattccag	9360
ggattccaga gttacagcac atgcatacct ccatccaagc atgtttatth gtctcctgct	9420
tcactaggct gtccccaagg aacatgtggc tcccggcaca tacctggcac aacactgcac	9480
atgacattca cccacttggc cttgaatctg acaaggaatc tggcatgatg ttcacctgct	9540
gaggccagggt gccgagcagc cctggaggct tagggggccag agggatggga aaaggtgtct	9600
ttctgggggtg agtatcagtt tctgcaggag tgctgaacct gagaaagaat aaagagagaa	9660
ggaagtgaac aagcacagct taaacatcat ctgtttctac tgagttttta caactctgag	9720
atthttgtttg tcatggaatc catttctcag gccaaagcaga cacagaactt ggggtgtgagt	9780

- 7 -

```

gatgataatg agctgatata attttcacac cctcatcact gagatctctc ccatcaggaa 9840
tgggtcacag ggctcacagg tggcagcaac tgttattaca ggctcatct ctaccagctc 9900
ctggcacctg ctctcctctc attagaaaat cctccacttg tcaaaaagga agccatttgc 9960
tttgaattcc aattccaccc tcaagaggct gggaccacct cattggagtc cttgatgctg 10020
tgtgacctgc agtgaccact gccccattgt tgctggctga ggtggtttgg gtcaacctgg 10080
ccatctgggc agctgttctc ttctcttctt tctccctac tgtttccaga catgcagtat 10140
ttccagagag aagggggccac tctttggcaa agaacctgtc taactttcta tctacggcag 10200
gacttttgaa agctacagag gaagaagcac aaattgatgc tattccacta agccatcagc 10260
tccatctcat ccatgccatg tctctttttt aggggtcctc ttgccaacag aatcacagag 10320
gacaaatctg aaagtgcaga gacagcagct gaggcacagc caagagctct ggctgtatta 10380
atgacctaa aagatggagt ggtcaccaga aagtcagagg aagtgcaca caggggcccc 10440
gcaatctcag ccaagtcaac tccaccagcc tttctggtcc cactgtgtg tacagcacc 10500
tgatagggac cagagccatg agagttagta agaccagact atgcccttga ggagctcacc 10560
tctgctaagg gaaacaggcc tggaaacaca caatggtggt aaagaggaaa gaagacaata 10620
gaactgcatg aaggggatgg aaagtgccca ggggaggaaa tggttacttc tgtgtgaggg 10680
ggttggtgag gaaagactct aagagaaggc tctgtctggc tgggtatgaa aggatgtgta 10740
ggagtcttct aggggggcaca ggcacactcc aggcataagg aaagatctgt aggcattggct 10800
tgttgggatg agtttcaagt attctggaat gaggacagcc atagagacaa gaggagagtt 10860
aatagatttt atgccaatgg ctccacttga gtttgtgata agaaccacaga acccttggac 10920
tccccagtaa cattgattga gttgtgtatg attctacata gaatattaac tcaatggagg 10980
tcagtgagtg gtgtgtgtgt gattatttgc caactgccga ggtggagaag cctcttccga 11040
ctgcaggcag agcacggggg cctgctact ggctgcagct ccagccctgc ctcttctcc 11100
agcatataaa caatccaaca gcctcactga atcactgctg tgcagggcag gaaagctcca 11160
cacacacagc ccagcaaaca gcagca 11186

```

```

<210> 2
<211> 1971
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> CDS
<222> (4)..(1515)

```

- 8 -

<300>

<308> GenBank/NM_000765

<309> 1999-03-19

<400> 2

gtg atg gat ctc atc cca aac ttg gcc gtg gaa acc tgg ctt ctc ctg	48
Met Asp Leu Ile Pro Asn Leu Ala Val Glu Thr Trp Leu Leu Leu	
1 5 10 15	
 gct gtc agc ctg ata ctc ctc tat cta tat gga acc cgt aca cat gga	 96
Ala Val Ser Leu Ile Leu Leu Tyr Leu Tyr Gly Thr Arg Thr His Gly	
20 25 30	
 ctt ttt aag aag ctt gga att cca ggg ccc aca cct ctg cct ttt ttg	 144
Leu Phe Lys Lys Leu Gly Ile Pro Gly Pro Thr Pro Leu Pro Phe Leu	
35 40 45	
 gga aat gct ttg tcc ttc cgt aag ggc tat tgg acg ttt gac atg gaa	 192
Gly Asn Ala Leu Ser Phe Arg Lys Gly Tyr Trp Thr Phe Asp Met Glu	
50 55 60	
 tgt tat aaa aag tat aga aaa gtc tgg ggt att tat gac tgt caa cag	 240
Cys Tyr Lys Lys Tyr Arg Lys Val Trp Gly Ile Tyr Asp Cys Gln Gln	
65 70 75	
 cct atg ctg gct atc aca gat ccc gac atg atc aaa aca gtg cta gtg	 288
Pro Met Leu Ala Ile Thr Asp Pro Asp Met Ile Lys Thr Val Leu Val	
80 85 90 95	
 aaa gaa tgt tat tct gtc ttc aca aac cgg agg cct ttc ggg cca gtg	 336
Lys Glu Cys Tyr Ser Val Phe Thr Asn Arg Arg Pro Phe Gly Pro Val	
100 105 110	
 gga ttt atg aaa aat gcc atc tct ata gct gag gat gaa gaa tgg aag	 384
Gly Phe Met Lys Asn Ala Ile Ser Ile Ala Glu Asp Glu Glu Trp Lys	
115 120 125	
 aga ata cga tca ttg ctg tct cca aca ttc acc agc gga aaa ctc aag	 432
Arg Ile Arg Ser Leu Leu Ser Pro Thr Phe Thr Ser Gly Lys Leu Lys	
130 135 140	
 gag atg gtc cct atc att gcc cag tat gga gat gtg ttg gtg aga aat	 480
Glu Met Val Pro Ile Ile Ala Gln Tyr Gly Asp Val Leu Val Arg Asn	
145 150 155	
 ctg agg cgg gaa gca gag aca ggc aag cct gtc acc ttg aaa cac gtc	 528
Leu Arg Arg Glu Ala Glu Thr Gly Lys Pro Val Thr Leu Lys His Val	
160 165 170 175	
 ttt ggg gcc tac agc atg gat gtg atc act agc aca tca ttt gga gtg	 576
Phe Gly Ala Tyr Ser Met Asp Val Ile Thr Ser Thr Ser Phe Gly Val	
180 185 190	

- 9 -

agc atc gac tct ctc aac aat cca caa gac ccc ttt gtg gaa aac acc	624
Ser Ile Asp Ser Leu Asn Asn Pro Gln Asp Pro Phe Val Glu Asn Thr	
195 200 205	
aag aag ctt tta aga ttt aat cca tta gat cca ttc gtt ctc tca ata	672
Lys Lys Leu Leu Arg Phe Asn Pro Leu Asp Pro Phe Val Leu Ser Ile	
210 215 220	
aaa gtc ttt cca ttc ctt acc cca att ctt gaa gca tta aat atc act	720
Lys Val Phe Pro Phe Leu Thr Pro Ile Leu Glu Ala Leu Asn Ile Thr	
225 230 235	
gtg ttt cca aga aaa gtt ata agt ttt cta aca aaa tct gta aaa cag	768
Val Phe Pro Arg Lys Val Ile Ser Phe Leu Thr Lys Ser Val Lys Gln	
240 245 250 255	
ata aaa gaa ggt cgc ctc aaa gag aca caa aag cac cga gtg gat ttc	816
Ile Lys Glu Gly Arg Leu Lys Glu Thr Gln Lys His Arg Val Asp Phe	
260 265 270	
ctt cag ctg atg att gac tct cag aat tca aaa gac tct gag acc cac	864
Leu Gln Leu Met Ile Asp Ser Gln Asn Ser Lys Asp Ser Glu Thr His	
275 280 285	
aaa gct ctg tct gat ctg gag ctc atg gcc caa tca att atc ttt att	912
Lys Ala Leu Ser Asp Leu Glu Leu Met Ala Gln Ser Ile Ile Phe Ile	
290 295 300	
ttt gct ggc tat gaa acc acg agc agt gtt ctc tcc ttc att ata tat	960
Phe Ala Gly Tyr Glu Thr Thr Ser Ser Val Leu Ser Phe Ile Ile Tyr	
305 310 315	
gaa ctg gcc act cac cct gat gtc cag cag aaa gtg cag aag gaa att	1008
Glu Leu Ala Thr His Pro Asp Val Gln Gln Lys Val Gln Lys Glu Ile	
320 325 330 335	
gat aca gtt tta ccc aat aag gca cca ccc acc tat gat act gtg cta	1056
Asp Thr Val Leu Pro Asn Lys Ala Pro Pro Thr Tyr Asp Thr Val Leu	
340 345 350	
cag ttg gag tat ctt gac atg gtg gtg aat gaa aca ctc aga tta ttc	1104
Gln Leu Glu Tyr Leu Asp Met Val Val Asn Glu Thr Leu Arg Leu Phe	
355 360 365	
cca gtt gct atg aga ctt gag agg gtc tgc aaa aaa gat gtt gaa atc	1152
Pro Val Ala Met Arg Leu Glu Arg Val Cys Lys Lys Asp Val Glu Ile	
370 375 380	
aat ggg atg ttt att ccc aaa ggg gtg gtg gtg atg att cca agc tat	1200
Asn Gly Met Phe Ile Pro Lys Gly Val Val Val Met Ile Pro Ser Tyr	
385 390 395	
gtt ctt cat cat gac cca aag tac tgg aca gag cct gag aag ttc ctc	1248
Val Leu His His Asp Pro Lys Tyr Trp Thr Glu Pro Glu Lys Phe Leu	
400 405 410 415	

- 10 -

cct gaa agg ttc agt aaa aag aac aag gac aac ata gat cct tac ata 1296
 Pro Glu Arg Phe Ser Lys Lys Asn Lys Asp Asn Ile Asp Pro Tyr Ile
 420 425 430
 tac aca ccc ttt gga agt gga ccc aga aac tgc att ggc atg agg ttt 1344
 Tyr Thr Pro Phe Gly Ser Gly Pro Arg Asn Cys Ile Gly Met Arg Phe
 435 440 445
 gct ctc gtg aac atg aaa ctt gct cta gtc aga gtc ctt cag aac ttc 1392
 Ala Leu Val Asn Met Lys Leu Ala Leu Val Arg Val Leu Gln Asn Phe
 450 455 460
 tcc ttc aaa cct tgt aaa gaa aca cag atc ccc ctg aaa tta cgc ttt 1440
 Ser Phe Lys Pro Cys Lys Glu Thr Gln Ile Pro Leu Lys Leu Arg Phe
 465 470 475
 gga gga ctt ctt cta aca gaa aaa ccc att gtt cta aag gct gag tca 1488
 Gly Gly Leu Leu Leu Thr Glu Lys Pro Ile Val Leu Lys Ala Glu Ser
 480 485 490 495
 agg gat gag acc gta agt gga gcc tga tttccctaag gacttctggt 1535
 Arg Asp Glu Thr Val Ser Gly Ala
 500
 ttgctcttta agaaagctgt gccccagaac accagagacc tcaaattact ttacaaatag 1595
 aaccctgaaa tgaagacggg cttcatccaa tgtgctgcat aaataatcag ggattctgta 1655
 cgtgcattgt gctctctcat ggtctgtata gagtgttata cttggtaata tagaggagat 1715
 gaccaaataca gtgctgggga agtagatttg gcttctctgc ttctcatagg actatctcca 1775
 ccacccccag ttagcaccat taactcctcc tgagctctga taacataatt aacatttctc 1835
 aataatttca accacaatca ttaataaaaa taggaattat tttgatggct ctaacagtga 1895
 catttatatc atgtgttata tctgtagtat tctatagtaa gctttatatt aagcaaataca 1955
 ataaaaacct ctttac 1971

<210> 3
 <211> 503
 <212> PRT
 <213> Homo sapiens

<400> 3

Met Asp Leu Ile Pro Asn Leu Ala Val Glu Thr Trp Leu Leu Leu Ala
 1 5 10 15
 Val Ser Leu Ile Leu Leu Tyr Leu Tyr Gly Thr Arg Thr His Gly Leu
 20 25 30
 Phe Lys Lys Leu Gly Ile Pro Gly Pro Thr Pro Leu Pro Phe Leu Gly
 35 40 45

- 11 -

Asn	Ala	Leu	Ser	Phe	Arg	Lys	Gly	Tyr	Trp	Thr	Phe	Asp	Met	Glu	Cys	50	55	60	
Tyr	Lys	Lys	Tyr	Arg	Lys	Val	Trp	Gly	Ile	Tyr	Asp	Cys	Gln	Gln	Pro	65	70	75	80
Met	Leu	Ala	Ile	Thr	Asp	Pro	Asp	Met	Ile	Lys	Thr	Val	Leu	Val	Lys	85	90	95	
Glu	Cys	Tyr	Ser	Val	Phe	Thr	Asn	Arg	Arg	Pro	Phe	Gly	Pro	Val	Gly	100	105	110	
Phe	Met	Lys	Asn	Ala	Ile	Ser	Ile	Ala	Glu	Asp	Glu	Glu	Trp	Lys	Arg	115	120	125	
Ile	Arg	Ser	Leu	Leu	Ser	Pro	Thr	Phe	Thr	Ser	Gly	Lys	Leu	Lys	Glu	130	135	140	
Met	Val	Pro	Ile	Ile	Ala	Gln	Tyr	Gly	Asp	Val	Leu	Val	Arg	Asn	Leu	145	150	155	160
Arg	Arg	Glu	Ala	Glu	Thr	Gly	Lys	Pro	Val	Thr	Leu	Lys	His	Val	Phe	165	170	175	
Gly	Ala	Tyr	Ser	Met	Asp	Val	Ile	Thr	Ser	Thr	Ser	Phe	Gly	Val	Ser	180	185	190	
Ile	Asp	Ser	Leu	Asn	Asn	Pro	Gln	Asp	Pro	Phe	Val	Glu	Asn	Thr	Lys	195	200	205	
Lys	Leu	Leu	Arg	Phe	Asn	Pro	Leu	Asp	Pro	Phe	Val	Leu	Ser	Ile	Lys	210	215	220	
Val	Phe	Pro	Phe	Leu	Thr	Pro	Ile	Leu	Glu	Ala	Leu	Asn	Ile	Thr	Val	225	230	235	240
Phe	Pro	Arg	Lys	Val	Ile	Ser	Phe	Leu	Thr	Lys	Ser	Val	Lys	Gln	Ile	245	250	255	
Lys	Glu	Gly	Arg	Leu	Lys	Glu	Thr	Gln	Lys	His	Arg	Val	Asp	Phe	Leu	260	265	270	
Gln	Leu	Met	Ile	Asp	Ser	Gln	Asn	Ser	Lys	Asp	Ser	Glu	Thr	His	Lys	275	280	285	
Ala	Leu	Ser	Asp	Leu	Glu	Leu	Met	Ala	Gln	Ser	Ile	Ile	Phe	Ile	Phe	290	295	300	
Ala	Gly	Tyr	Glu	Thr	Thr	Ser	Ser	Val	Leu	Ser	Phe	Ile	Ile	Tyr	Glu	305	310	315	320
Leu	Ala	Thr	His	Pro	Asp	Val	Gln	Gln	Lys	Val	Gln	Lys	Glu	Ile	Asp	325	330	335	
Thr	Val	Leu	Pro	Asn	Lys	Ala	Pro	Pro	Thr	Tyr	Asp	Thr	Val	Leu	Gln	340	345	350	

- 12 -

Leu Glu Tyr Leu Asp Met Val Val Asn Glu Thr Leu Arg Leu Phe Pro
 355 360 365
 Val Ala Met Arg Leu Glu Arg Val Cys Lys Lys Asp Val Glu Ile Asn
 370 375 380
 Gly Met Phe Ile Pro Lys Gly Val Val Val Met Ile Pro Ser Tyr Val
 385 390 395 400
 Leu His His Asp Pro Lys Tyr Trp Thr Glu Pro Glu Lys Phe Leu Pro
 405 410 415
 Glu Arg Phe Ser Lys Lys Asn Lys Asp Asn Ile Asp Pro Tyr Ile Tyr
 420 425 430
 Thr Pro Phe Gly Ser Gly Pro Arg Asn Cys Ile Gly Met Arg Phe Ala
 435 440 445
 Leu Val Asn Met Lys Leu Ala Leu Val Arg Val Leu Gln Asn Phe Ser
 450 455 460
 Phe Lys Pro Cys Lys Glu Thr Gln Ile Pro Leu Lys Leu Arg Phe Gly
 465 470 475 480
 Gly Leu Leu Leu Thr Glu Lys Pro Ile Val Leu Lys Ala Glu Ser Arg
 485 490 495
 Asp Glu Thr Val Ser Gly Ala
 500

<210> 4
 <211> 1012
 <212> DNA
 <213> Homo sapiens

<300>
 <308> GenBank/AF181861
 <309> 1999-09-15

<400> 4
 tcctgtttcc agacatgcag tatttccaga gagaaggggc cactcttttg caaagaacct 60
 gtctaacttt ctatctacgg caggactttt gaaagctaca gaggaagaag cacaattga 120
 tgctattcca ctaagccatc agtccatct catccatgcc atgtctcttt tttaggggtc 180
 ctcttgccaa cagaatcaca gaggacaaat ctgaaagtgc agagacagca gctgaggcac 240
 agccaagagc tctggctgta ttaatgacct aagaagatgg agtggtcacc agaaagtcag 300
 aggaagtgc acacaggggc ccagcaatct cagccaagtc aactccacca gcctttctgg 360
 tccccactgt gtgtacagca ccctgatagg gaccagagcc atgagagtga gtaagaccag 420
 actatgccct tgaggagctc acctctgcta agggaaacag gcctggaaac acacaatggt 480

- 13 -

ggtaaagagg aaagaagaca atagaactgc atgaagggga tggaaagtgc ccaggggagg	540
aaatgggttac ttctgtgtga ggggggttgt gaggaagac totaagagaa ggctctgtct	600
ggctgggtat gaaaggatgt gtaggagtct tctagggggc acaggcacac tccaggcata	660
ggtaaagatc tgtaggcatg gcttggtggg atgagtttca agtattctgg aatgaggaca	720
gccatagaga caagaggaga gttaatagat ttatgccaa tggctccact tgagtttgtg	780
ataagaacc agaacccttg gactccccag taacattgat tgagtttgt atgattctac	840
atagaatatt aactcaatgg aggtcagtga gtggtgtgtg tgtgattatt tgccaactgc	900
cgaggtggag aagcctcttc cgactgcagg cagagcacgg gggccctgct actggctgca	960
gctccagccc tgctccttc tccagcatat aaacaatcca acagcctcac tg	1012

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C12N 15/53, C12N 9/02, C12Q 1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI-DATA, PAJ, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9961622 A1 (THE UNIVERSITY OF SYDNEY), 2 December 1999 (02.12.99), especially pages 2-5 & 11 and SEQ. ID. NO 2,385	1-12
Y	page 3 - page 4 --	8
Y	US 5726041 A (CHARLES L. CHRESPI ET AL), 10 March 1998 (10.03.98), abstract --	8
A	WO 0023596 A1 (BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM), 27 April 2000 (27.04.00) -- -----	13-18

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

24 January 2002

Date of mailing of the international search report

26-01-2002

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Carl-Olof Gustafsson/EÖ
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

Information on patent family members

27/12/02

International application No.

PCT/SE 01/02007

Patent document cited in search report			Publication date	Patent family member(s)			Publication date
WO	9961622	A1	02/12/99	AU	4023299	A	13/12/99
				AU	PP362898	D	00/00/00
				EP	1082437	A	14/03/01

US	5726041	A	10/03/98	WO	9708342	A	06/03/97

WO	0023596	A1	27/04/00	AU	1450600	A	08/05/00
